NCT02738814

Brief Summary

This study aimed to verify the effects of propofol for treatment on emergence agitation (EA) after sevoflurane anesthesia in pediatric strabismus surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Apr 2016

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 14, 2016

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

April 14, 2016

Status Verified

April 1, 2016

Enrollment Period

6 months

First QC Date

March 1, 2016

Last Update Submit

April 13, 2016

Conditions

Keywords

emergence agitationemergence deliriumPAED scaleThe Modified Aldrete Scoring Systemtreatmentpediatricsevoflurane

Outcome Measures

Primary Outcomes (1)

  • Change of Emergent Adverse Events [Safety and Tolerability]

    After anesthetic emergence, investigator, nurse and attending anesthesiologist check the PAED scale every 5min, up to 2 hours until discharge from PACU. If checked PAED scale is 14 or more, attending anesthesiologist administers 1% propofol 0.8\~1.0mg/kg(sedative dose). Then they check PAED scale every 5min after the arousal from sedative state until the discharge from PACU.

    From just after extubation until the discharge from PACU, assessed up to 2 hours.

Secondary Outcomes (1)

  • Duration of PACU stay

    From the arrival of the PACU to discharge from the PACU, assessed an average of 1hour

Study Arms (2)

PAED > 13

EXPERIMENTAL

When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.

Drug: propofol

PAED < 14

NO INTERVENTION

Caregivers must first try to reassure patients.

Interventions

When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.

Also known as: fresofol MCT 1%
PAED > 13

Eligibility Criteria

Age3 Years - 10 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • ASA (american society of anesthesiologists) physical status patients, aged 3-10yr, presenting for elective strabismus surgery.

You may not qualify if:

  • Refusal by parents, neurologic disease, developmental delay, history of any previous surgery, American society of Anesthesiologists physical status score of III or IV, and airway disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Korea University Medical Center, Anam hospital

Seoul, Seongbuk-gu, 136-705, South Korea

Location

Related Publications (1)

  • Xu GS, Yoon SZ, Choi YJ, Shin HW, Kim JH. Postoperative propofol bolus treatment did not affect recovery time in patients with emergence agitation after sevoflurane anesthesia in pediatric patients undergoing strabismus surgery: Prospective nonrandomized case-control study. Medicine (Baltimore). 2022 Jul 15;101(28):e29521. doi: 10.1097/MD.0000000000029521.

MeSH Terms

Conditions

Emergence Delirium

Interventions

Propofol

Condition Hierarchy (Ancestors)

DeliriumConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and SymptomsNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • SeungZhoo Yoon, M.D.PhD.

    Department of Anesthesiology and Pain medicine. Korea universicy medical center.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident

Study Record Dates

First Submitted

March 1, 2016

First Posted

April 14, 2016

Study Start

April 1, 2016

Primary Completion

October 1, 2016

Study Completion

December 1, 2016

Last Updated

April 14, 2016

Record last verified: 2016-04

Data Sharing

IPD Sharing
Will not share

Locations